Press Releases Can-Fite BioPharma Ltd.

Equities

CANF

IL0010944739

Market Closed - TEL AVIV STOCK EXCHANGE Other stock markets 10:24:13 2024-05-16 EDT			5-day change	1st Jan Change
2.6 ^ILa	-3.70%		-3.70%	0.00%

05-12	Transcript : Can-Fite BioPharma Ltd. - Special Call
05-09	Can-Fite BioPharma Ltd. Announces FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Can Fite BioPharma : Immediate Report	05-13	PU
Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study	05-13	BU
CAN-FITE, FDA GRANTS IND CLEARANCE FOR NAMODENOSON TO TREAT MASH PATIENTS IN A PHASE IIB STUDY	05-10	AQ
Can Fite BioPharma : FDA grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study	05-09	PU
Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study	05-09	BU
Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602	05-06	BU
LONG-TERM COMPLETE RESPONSE TO CAN-FITE'S NAMODENOSON IN PATIENT WITH ADVANCED LIVER CANCER ARTICLE PUBLISHED IN A LEADING SCIENTIFIC JOURNAL	04-26	AQ
Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal	04-25	BU
CAN-FITE, SCIENTIFIC ARTICLE PUBLISHED BY KOL PRESENTS NAMODENOSON AS A PROMISING DRUG CANDIDATE TO TREAT ADVANCED LIVER CANCER AND MASH	04-16	AQ
Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH	04-15	BU
Can Fite BioPharma : Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH	04-15	PU
Can Fite BioPharma : Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients	04-03	PU
Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients	04-03	BU
Can-Fite BioPharma, Ltd. to Present at the LD Micro Invitational XIV	04-01	NE
Can Fite BioPharma : 20F FOR 2023	03-28	PU
Can-Fite Reports 2023 Financial Results and Clinical Update	03-28	BU
Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference	03-11	BU
CAN-FITE BROADENS ITS STRONG INTELLECTUAL PROPERTY FOR NASH, RECEIVED PATENT ALLOWANCE IN CANADA	02-29	AQ
Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada	02-28	BU
CAN-FITE, TOP SCIENTIFIC JOURNAL PUBLISHED POSITIVE DATA FROM THE COMFORT-1 PHASE III PSORIASIS STUDY	01-30	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Can-Fite BioPharma Ltd.

Equities

CANF

IL0010944739

Press Releases

Filters